BACKGROUND/ OBJECTIVES:Vitamin D has anti-inflammatory and immune-regulating properties. We aimed to determine if high-dose cholecalciferol supplementation for 1 year in subjects with early chronic kidney disease (CKD) improved circulating markers of inflammation and immunity. SUBJECTS/ METHODS: In this double-blind, randomized, placebo-controlled trial, 46 subjects with early CKD (stages 2 and 3) were supplemented with oral cholecalciferol (50 000 IU weekly for 12 weeks followed by 50 000 IU every other week for 40 weeks) or a matching placebo for 1 year. Serum tumor necrosis factor-α, interleukin-6, monocyte chemoattractant protein-1 (MCP-1), interferon gamma-induced protein-10 and neutrophil gelatinase-associated lipocalin were measured at baseline, 12 weeks and 1 year. Serum cathelicidin (LL-37) was measured at baseline and 12 weeks. An in vitro experiment was performed to investigate the effect of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) treatment on MCP-1 secretion in THP-1 monocytes activated with lipopolysaccharide (LPS) and Pseudomonas aeruginosa. RESULTS: By 12 weeks, serum MCP-1 decreased in the cholecalciferol group (66.2±2.5 to 60.8±2.6 pg/ml, group-by-time interaction P=0.02) but was not different from baseline at 1 year. Other markers of inflammation and immunity did not change. In vitro, LPS- and Pseudomonas-activated monocytes treated with 1,25(OH)2D3 had significantly less MCP-1 secretion compared with untreated cells. CONCLUSIONS:High-dose cholecalciferol decreased serum MCP-1 concentrations by 12 weeks in patients with early CKD, although the decrease was not maintained for the remainder of the year. In vitro results confirm an MCP-1-lowering effect of vitamin D. Future studies should determine if vitamin D-mediated reductions in MCP-1 concentrations reflect improved clinical outcomes.
RCT Entities:
BACKGROUND/ OBJECTIVES:Vitamin D has anti-inflammatory and immune-regulating properties. We aimed to determine if high-dose cholecalciferol supplementation for 1 year in subjects with early chronic kidney disease (CKD) improved circulating markers of inflammation and immunity. SUBJECTS/ METHODS: In this double-blind, randomized, placebo-controlled trial, 46 subjects with early CKD (stages 2 and 3) were supplemented with oral cholecalciferol (50 000 IU weekly for 12 weeks followed by 50 000 IU every other week for 40 weeks) or a matching placebo for 1 year. Serum tumor necrosis factor-α, interleukin-6, monocyte chemoattractant protein-1 (MCP-1), interferon gamma-induced protein-10 and neutrophil gelatinase-associated lipocalin were measured at baseline, 12 weeks and 1 year. Serum cathelicidin (LL-37) was measured at baseline and 12 weeks. An in vitro experiment was performed to investigate the effect of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) treatment on MCP-1 secretion in THP-1 monocytes activated with lipopolysaccharide (LPS) and Pseudomonas aeruginosa. RESULTS: By 12 weeks, serum MCP-1 decreased in the cholecalciferol group (66.2±2.5 to 60.8±2.6 pg/ml, group-by-time interaction P=0.02) but was not different from baseline at 1 year. Other markers of inflammation and immunity did not change. In vitro, LPS- and Pseudomonas-activated monocytes treated with 1,25(OH)2D3 had significantly less MCP-1 secretion compared with untreated cells. CONCLUSIONS: High-dose cholecalciferol decreased serum MCP-1 concentrations by 12 weeks in patients with early CKD, although the decrease was not maintained for the remainder of the year. In vitro results confirm an MCP-1-lowering effect of vitamin D. Future studies should determine if vitamin D-mediated reductions in MCP-1 concentrations reflect improved clinical outcomes.
Authors: Manuel Naves-Díaz; Daniel Alvarez-Hernández; Jutta Passlick-Deetjen; Adrian Guinsburg; Cristina Marelli; Diego Rodriguez-Puyol; Jorge B Cannata-Andía Journal: Kidney Int Date: 2008-07-16 Impact factor: 10.612
Authors: Andrew S Levey; Josef Coresh; Tom Greene; Lesley A Stevens; Yaping Lucy Zhang; Stephen Hendriksen; John W Kusek; Frederick Van Lente Journal: Ann Intern Med Date: 2006-08-15 Impact factor: 25.391
Authors: John S Adams; Songyang Ren; Philip T Liu; Rene F Chun; Venu Lagishetty; Adrian F Gombart; Niels Borregaard; Robert L Modlin; Martin Hewison Journal: J Immunol Date: 2009-04-01 Impact factor: 5.422
Authors: Alexandra V Yamshchikov; Nirali S Desai; Henry M Blumberg; Thomas R Ziegler; Vin Tangpricha Journal: Endocr Pract Date: 2009 Jul-Aug Impact factor: 3.443
Authors: Leo Jeng; Alexandra V Yamshchikov; Suzanne E Judd; Henry M Blumberg; Gregory S Martin; Thomas R Ziegler; Vin Tangpricha Journal: J Transl Med Date: 2009-04-23 Impact factor: 5.531
Authors: M D Kearns; J N G Binongo; D Watson; J A Alvarez; D Lodin; T R Ziegler; V Tangpricha Journal: Eur J Clin Nutr Date: 2014-10-01 Impact factor: 4.016
Authors: Jessica A Alvarez; Ritam Chowdhury; Dean P Jones; Greg S Martin; Kenneth L Brigham; José N Binongo; Thomas R Ziegler; Vin Tangpricha Journal: Clin Endocrinol (Oxf) Date: 2014-04-15 Impact factor: 3.478
Authors: Petr Protiva; Swaroop Pendyala; Celeste Nelson; Leonard H Augenlicht; Martin Lipkin; Peter R Holt Journal: Am J Clin Nutr Date: 2016-03-23 Impact factor: 7.045
Authors: Helen F Titmarsh; Adam G Gow; Scott Kilpatrick; Jennifer A Cartwright; Elspeth M Milne; Adrian W Philbey; Jacqueline Berry; Ian Handel; Richard J Mellanby Journal: PLoS One Date: 2015-09-02 Impact factor: 3.240